Latest Breaking News On - Dustin sjuts - Page 1 : comparemela.com

Health Care Notes: Revance announces 2023 revenue jump, Q4 results

Also: Meharry lands clinical trial outreach grant; Sarah Cannon Research Institute announces partnership with AstraZeneca

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

28.02.2024 - Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. Financial Highlights Total revenue for the fourth quarter 2023 was $69.8 .

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023.

Revance Therapeutics Shares Slide on Guidance Shortfall

By Colin Kellaher Revance Therapeutics shares fell more than 15% on Monday after the biotechnology company's guidance fell short of Wall Street's.

Revance Therapeutics Stock: Not Even Daxxify Can Treat Investor Frown Lines (NASDAQ:RVNC)